Abstract
Taking into consideration the latest reported beneficial anticolvusant effects of cannabidiol (CBD) and cannabiodiolic acid (CBDA) for clinical applications and the advantages of lipid nano-systems as carriers for targeted brain delivery, the aim of this study was set in direction of in vitro physico-chemical and biopharmaceutical characterization and in vivo evaluation of nanoliposomes and nanostructured lipid carriers loaded with Cannabis sativa extract intended for safe and efficient transport via blood-brain barrier and treatment of epilepsy. These nanoliposomes and nanostructured lipid formulations were characterized with z-average diameter <200 nm, following unimodal particle size distribution, negative values for Z-potential, high drug encapsulation efficiency and prolonged release during 24h (38.84-60.91 %). Prepared formulations showed statistically significant higher antioxidant capacity compared to the extract. The results from in vivo studies of the anticonvulsant activity demonstrated that all formulations significantly elevated the latencies for myoclonic, clonic and tonic seizures and, therefore, could be used in preventing different types of seizures. A distinction in the potential of the nano-systems was noted, which was probably anticipated by the type and the characteristics of the prepared formulations.
Keywords: Anticonvulsant activity, Blood-brain barrier, Cannabidiolic acid, Cannabis sativa extract, Epilepsy, Nanoliposomes, Nanostructured lipid carriers
Copyright © 2022 American Pharmacists Association. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Similar articles
-
Abstracts of Presentations at the Association of Clinical Scientists 143rd Meeting Louisville, KY May 11-14,2022.Ann Clin Lab Sci. 2022 May;52(3):511-525.PMID: 35777803
-
Isolation, Purification, and Antimicrobial Characterization of Cannabidiolic Acid and Cannabidiol from Cannabis sativa L.Biomolecules. 2020 Jun 12;10(6):900. doi: 10.3390/biom10060900.PMID: 32545687 Free PMC article.
-
Nanostructured lipid carriers-mediated brain delivery of carbamazepine for improved in vivo anticonvulsant and anxiolytic activity.Int J Pharm. 2020 Mar 15;577:119033. doi: 10.1016/j.ijpharm.2020.119033. Epub 2020 Jan 16.PMID: 31954864
-
Cannabis for the Treatment of Epilepsy: an Update.Curr Neurol Neurosci Rep. 2018 Sep 8;18(11):73. doi: 10.1007/s11910-018-0882-y.PMID: 30194563 Review.
-
Biochemical aspects and therapeutic mechanisms of cannabidiol in epilepsy.Neurosci Biobehav Rev. 2022 Jan;132:1214-1228. doi: 10.1016/j.neubiorev.2020.09.027. Epub 2020 Oct 5.PMID: 33031814 Review.